½ÃÀ庸°í¼­
»óǰÄÚµå
1150085

¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, ¾÷°è ºÐ¼® : Àü¹® ºÐ¾ßº°, ±â¼úº°, Áúȯ À¯Çüº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2022-2030³â)

Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty ; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Polaris Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 119 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 24¾ï 1,490¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç(Rare Disease Genetic Testing) ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎ, Àü¹® ºÐ¾ßº°¡¤±â¼úº°¡¤Áúȯ À¯Çüº°¡¤ÃÖÁ¾ ¿ëµµº°¡¤Áö¿ªº° µîÀÇ ºÐ¼®, ±â¾÷ °³¿ä µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • º¸°í¼­ ¼³¸í
    • Á¶»ç ¸ñÀû
    • ½ÃÀå ¹üÀ§
    • ÀüÁ¦Á¶°Ç
  • ÀÌÇØ°ü°èÀÚ

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • °³¿ä
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
  • Á¤º¸¿ø
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸

Á¦4Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå ÀλçÀÌÆ®

  • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç - ¾÷°è ÇöȲ
  • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • PorterÀÇ »ê¾÷ ºÐ¼®
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ±â¾÷ÀÇ À§Çù
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • ´ëüǰÀÇ À§Çù
    • ±âÁ¸ ±â¾÷°£ °æÀï·Â
  • PESTLE ºÐ¼®
  • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ¾÷°è µ¿Çâ
  • ¹ë·ùüÀÎ ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦5Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : ±â¼úº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ±â¼úº°(2018-2030³â)
  • Â÷¼¼´ë ½ÃÄö½Ì
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Â÷¼¼´ë ½ÃÄö½Ì, Áö¿ªº°(2018-2030³â)
    • Whole Exome
    • Whole Genome
  • ¾î·¹ÀÌ ±â¼ú
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ¾î·¹ÀÌ ±â¼úº°, Áö¿ªº°(2018-2030³â)
  • PCR ±â¹Ý °Ë»ç
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, PCR ±â¹Ý °Ë»ç, Áö¿ªº°(2018-2030³â)
  • FISH
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, FISH, Áö¿ªº°(2018-2030³â)
  • Sanger Sequencing
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Sanger Sequencing, Áö¿ªº°(2018-2030³â)
  • Karyotyping
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Karyotyping, Áö¿ªº°(2018-2030³â)

Á¦6Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : Àü¹® ºÐ¾ßº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Àü¹® ºÐ¾ßº°(2018-2030³â)
  • ºÐÀÚÀ¯ÀüÇÐÀû °Ë»ç
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ºÐÀÚÀ¯ÀüÇÐÀû °Ë»ç, Áö¿ªº°(2018-2030³â)
  • ¿°»öü À¯ÀüÀÚ °Ë»ç
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ¿°»öü À¯ÀüÀÚ °Ë»ç, Áö¿ªº°(2018-2030³â)
  • »ýÈ­ÇÐÀû À¯ÀüÀÚ °Ë»ç
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, »ýÈ­ÇÐÀû À¯ÀüÀÚ °Ë»ç, Áö¿ªº°(2018-2030³â)

Á¦7Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : Áúȯ À¯Çüº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Áúȯ À¯Çüº°(2018-2030³â)
  • ½Å°æÁúȯ
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ½Å°æÁúȯº°, Áö¿ªº°(2018-2030³â)
  • ¸é¿ªÁúȯ
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ¸é¿ªÁúȯº°, Áö¿ªº°(2018-2030³â)
  • Ç÷¾×Áúȯ
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Ç÷¾×Áúȯº°, Áö¿ªº°(2018-2030³â)
  • ³»ºÐºñÁúȯ/´ë»çÁúȯ
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ³»ºÐºñÁúȯ/´ë»çÁúȯº°, Áö¿ªº°(2018-2030³â)
  • ¾Ï
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ¾Ï, Áö¿ªº°(2018-2030³â)
  • ±Ù°ñ°Ý°è Áúȯ
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ±Ù°ñ°Ý°è Áúȯº°, Áö¿ªº°(2018-2030³â)
  • ½ÉÇ÷°üÁúȯ
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ½ÉÇ÷°üÁúȯº°, Áö¿ªº°(2018-2030³â)
  • ÇǺÎÁúȯ
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ÇǺÎÁúȯº°, Áö¿ªº°(2018-2030³â)
  • ±âŸ
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ±âŸ, Áö¿ªº°(2018-2030³â)

Á¦8Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
  • ¿¬±¸¼Ò/CRO
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ¿¬±¸¼Ò/CRO, Áö¿ªº°(2018-2030³â)
  • º´¿ø/Áø·á¼Ò
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, º´¿ø/Áø·á¼Ò, Áö¿ªº°(2018-2030³â)
  • Áø´Ü½ÇÇè½Ç
    • ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Áø´Ü½ÇÇè½Ç , Áö¿ªº°(2018-2030³â)

Á¦9Àå ¼¼°èÀÇ Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ¼­·Ð
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå Æò°¡, Áö¿ªº°(2018-2030³â)
  • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ºÏ¹Ì
    • ºÏ¹Ì : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ±â¼úº°(2018-2030³â)
    • ºÏ¹Ì : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • ºÏ¹Ì : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Àü¹® ºÐ¾ßº°(2018-2030³â)
    • ºÏ¹Ì : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Áúȯ À¯Çüº°(2018-2030³â)
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ¹Ì±¹
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ij³ª´Ù
  • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - À¯·´
    • À¯·´ : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ±â¼úº°(2018-2030³â)
    • À¯·´ : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • À¯·´ : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Àü¹® ºÐ¾ßº°(2018-2030³â)
    • À¯·´ : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Áúȯ À¯Çüº°(2018-2030³â)
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ¿µ±¹
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ÇÁ¶û½º
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - µ¶ÀÏ
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ÀÌÅ»¸®¾Æ
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ½ºÆäÀÎ
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ³×´ú¶õµå
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ·¯½Ã¾Æ
  • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ±â¼úº°(2018-2030³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Àü¹® ºÐ¾ßº°(2018-2030³â)
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Áúȯ À¯Çüº°(2018-2030³â)
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - Áß±¹
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - Àεµ
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ÀϺ»
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ¸»·¹À̽þÆ
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - Àεµ³×½Ã¾Æ
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - Çѱ¹
  • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ±â¼úº°(2018-2030³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Àü¹® ºÐ¾ßº°(2018-2030³â)
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Áúȯ À¯Çüº°(2018-2030³â)
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - »ç¿ìµð¾Æ¶óºñ¾Æ
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - À̽º¶ó¿¤
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä« : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ±â¼úº°(2018-2030³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, ÃÖÁ¾ ¿ëµµº°(2018-2030³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Àü¹® ºÐ¾ßº°(2018-2030³â)
    • ¶óƾ¾Æ¸Þ¸®Ä« : Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå, Áúȯ À¯Çüº°(2018-2030³â)
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ¸ß½ÃÄÚ
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ºê¶óÁú
    • Èñ±ÍÁúȯ À¯ÀüÀÚ °Ë»ç ½ÃÀå - ¾Æ¸£ÇîÆ¼³ª

Á¦10Àå °æÀï ±¸µµ

  • È®Àå ¹× Àμö ºÐ¼®
    • È®Àå
    • Àμö
  • ÆÄÆ®³Ê½Ê/Çù¾÷/ÇùÁ¤/°ø°³

Á¦11Àå ±â¾÷ °³¿ä

  • 3billion, Inc
  • Ambry Genetics
  • Artemis DNA
  • Arup Laboratories
  • Baylor Genetics
  • Centogene N.V
  • Color Genomics, Inc
  • Coopersurgical, Inc
  • Eurofins Scientific
  • Fulgent Genetics Inc
  • Genomenon
  • Health Network Laboratories
  • Invitae Corp
  • Laboratory Corporation of America Holdings
  • Macrogen, Inc
  • Myriad Genetics, Inc.
  • Opko Health, Inc
  • Perkin Elmer, Inc
  • PreventionGenetics
  • Progenity, Inc
  • Quest Diagnostics Inc.
  • Realm IDX, Inc
  • Strand Life Sciences.
LSH 22.12.02

The global rare disease genetic testing market size is expected to reach USD 2,414.90 million by 2030 according to a new study by Polaris Market Research. The report "Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty (Molecular Genetic Tests, Chromosomal Genetic Tests, Biochemical Genetic Tests); By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing technological advancements, including NGS and microarray, are prominent factors responsible for the market's growth. Also, the existence of Rare Diseases Clinical Research Network (RDCRN), an NIH-funded research network of 23 active research groups focused on the diagnosis & treatment of disorders, is anticipated to impact the industry positively. Furthermore, the decline in sequencing prices has shifted the attention to testing rare diseases, which has influenced the adoption of NGS, resulting in the market's growth.

Translational research and genomic technologies play a crucial role in accelerating the investigation and identification of new mutations, which aid in market expansion. Due to numerous translational research activities in this field, genetic testing in disease diagnostics is expected to rise rapidly throughout the projection period.

An increase in patient registry for rare diseases and development of new products to treat rare diseases are stimulating the growth of the market. The market is expected to grow as the number and quality of available registries continue to expand. So advanced data collection and interpretation technologies that can be used in clinical practices improve. An increasing number of patients undergoing disease testing, as well as increased government assistance, will fuel several new opportunities for market growth.

Rare Disease Genetic Testing Market Report Highlights

Endocrine and metabolism disease witnessed the largest market share in 2021 due to the growing number of patients with Cushing's syndrome.

The next-generation sequencing segment acquires significant market share due to increasing medical acceptance of whole exome sequencing-based gene tests.

Molecular genetic test segment is anticipated to hold considerable market share during the forecast period due to advanced testing technologies such as genome sequencing, which is affordable.

Research labs & CROs accounted largest market share in 2021 due to a large number of genetic tests performed in research laboratories and CROs.

North America dominated the market in 2021 due to the high prevalence of rare diseases and the abundance of registries in this region.

The global market is highly competitive owing to the existence of large industry players with a global presence of 3billion, Inc., Ambry Genetics, Artemis DNA, Arup Laboratories, Baylor Genetics, Centogene N.V., Color Genomics, Inc., Coopersurgical, Inc., Eurofins Scientific, Fulgent Genetics Inc., Genomenon, Health Network Laboratories, Invitae Corp., Laboratory Corporation of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., Opko Health, Inc., Perkin Elmer, Inc., PreventionGenetics, Progenity, Inc., Quest Diagnostics Inc., Realm IDX, Inc., and Strand Life Sciences.

Polaris Market Research has segmented the rare disease genetic testing market report based on disease type, technology, specialty, end-use, and regions:

Rare Disease Genetic Testing, Disease Type Outlook (Revenue - USD Million, 2018 - 2030)

Neurological disease

Immunological disorders

Hematology diseases

Endocrine and metabolism diseases

Cancer

Musculoskeletal disorders

Cardiovascular disorders

Dermatological disease

Others

Rare Disease Genetic Testing, Technology Outlook (Revenue - USD Million, 2018 - 2030)

Next-generation sequencing

Whole Exome

Whole Genome

Array Technology

PCR-based testing

FISH

Sanger Sequencing

Karyotyping

Rare Disease Genetic Testing, Specialty Outlook (Revenue - USD Million, 2018 - 2030)

Molecular genetic tests

Chromosomal genetic tests

Biochemical genetic tests

Rare Disease Genetic Testing, End-Use Outlook (Revenue - USD Million, 2018 - 2030)

Research Lab and CROs

Hospitals and Clinics

Diagnostic Laboratories

Rare Disease Genetic Testing, Regional Outlook (Revenue - USD Million, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Rare Disease Genetic Testing Market Insights

  • 4.1. Rare Disease Genetic Testing - Industry Snapshot
  • 4.2. Rare Disease Genetic Testing Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Expanding patient registry for rare disease
      • 4.2.1.2. Government & Regulatory Support For Rare Disease Diagnosis
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Awareness about The Rare Disease Conditions
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Rare Disease Genetic Testing Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Rare Disease Genetic Testing Market, by Technology

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
  • 5.3. Next-Generation Sequencing
    • 5.3.1. Global Rare Disease Genetic Testing Market, by Next-Generation Sequencing, by Region, 2018 - 2030 (USD Million)
    • 5.3.2. Whole Exome
      • 5.3.2.1. Global Rare Disease Genetic Testing Market, by Whole Exome, by Region, 2018 - 2030 (USD Million)
    • 5.3.3. Whole Genome
      • 5.3.3.1. Global Rare Disease Genetic Testing Market, by Whole Genome, by Region, 2018 - 2030 (USD Million)
  • 5.4. Array Technology
    • 5.4.1. Global Rare Disease Genetic Testing Market, by Array Technology, by Region, 2018 - 2030 (USD Million)
  • 5.5. PCR-based Testing
    • 5.5.1. Global Rare Disease Genetic Testing Market, by PCR-based Testing, by Region, 2018 - 2030 (USD Million)
  • 5.6. FISH
    • 5.6.1. Global Rare Disease Genetic Testing Market, by FISH, by Region, 2018 - 2030 (USD Million)
  • 5.7. Sanger Sequencing
    • 5.7.1. Global Rare Disease Genetic Testing Market, by Sanger Sequencing, by Region, 2018 - 2030 (USD Million)
  • 5.8. Karyotyping
    • 5.8.1. Global Rare Disease Genetic Testing Market, by Karyotyping, by Region, 2018 - 2030 (USD Million)

6. Global Rare Disease Genetic Testing Market, by Specialty

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
  • 6.3. Molecular Genetic Tests
    • 6.3.1. Global Rare Disease Genetic Testing Market, by Molecular Genetic Tests, by Region, 2018 - 2030 (USD Million)
  • 6.4. Chromosomal Genetic Tests
    • 6.4.1. Global Rare Disease Genetic Testing Market, by Chromosomal Genetic Tests, by Region, 2018 - 2030 (USD Million)
  • 6.5. Biochemical, Genetic Tests
    • 6.5.1. Global Rare Disease Genetic Testing Market, by Biochemical, Genetic Tests, by Region, 2018 - 2030 (USD Million)

7. Global Rare Disease Genetic Testing Market, by Disease Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
  • 7.3. Neurological Disease
    • 7.3.1. Global Rare Disease Genetic Testing Market, by Neurological Disease, by Region, 2018 - 2030 (USD Million)
  • 7.4. Immunological Disorders
    • 7.4.1. Global Rare Disease Genetic Testing Market, by Immunological Disorders, by Region, 2018 - 2030 (USD Million)
  • 7.5. Hematology Diseases
    • 7.5.1. Global Rare Disease Genetic Testing Market, by Hematology Diseases, by Region, 2018 - 2030 (USD Million)
  • 7.6. Endocrine & Metabolism Diseases
    • 7.6.1. Global Rare Disease Genetic Testing Market, by Endocrine & Metabolism Diseases, by Region, 2018 - 2030 (USD Million)
  • 7.7. Cancer
    • 7.7.1. Global Rare Disease Genetic Testing Market, by Cancer, by Region, 2018 - 2030 (USD Million)
  • 7.8. Musculoskeletal Disorders
    • 7.8.1. Global Rare Disease Genetic Testing Market, by Musculoskeletal Disorders, by Region, 2018 - 2030 (USD Million)
  • 7.9. Cardiovascular Disorders
    • 7.9.1. Global Rare Disease Genetic Testing Market, by Cardiovascular Disorders, by Region, 2018 - 2030 (USD Million)
  • 7.10. Dermatology Disease
    • 7.10.1. Global Rare Disease Genetic Testing Market, by Dermatology Disease, by Region, 2018 - 2030 (USD Million)
  • 7.11. Others
    • 7.11.1. Global Other Rare Disease Genetic Testing Market, by Region, 2018 - 2030 (USD Million)

8. Global Rare Disease Genetic Testing Market, by End-use

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
  • 8.3. Research Laboratories & Cros
    • 8.3.1. Global Rare Disease Genetic Testing Market, by Research Laboratories & Cros, by Region, 2018 - 2030 (USD Million)
  • 8.4. Hospitals & Clinics
    • 8.4.1. Global Rare Disease Genetic Testing Market, by Hospitals & Clinics, by Region, 2018 - 2030 (USD Million)
  • 8.5. Diagnostic Laboratories
    • 8.5.1. Global Rare Disease Genetic Testing Market, by Diagnostic Laboratories, by Region, 2018 - 2030 (USD Million)

9. Global Rare Disease Genetic Testing Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Rare Disease Genetic Testing Market Assessment, By Geography, 2018 - 2030 (USD Million)
  • 9.3. Rare Disease Genetic Testing Market - North America
    • 9.3.1. North America: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
    • 9.3.2. North America: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
    • 9.3.3. North America: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
    • 9.3.4. North America: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.3.5. Rare Disease Genetic Testing Market - U.S.
      • 9.3.5.1. U.S.: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.3.5.2. U.S.: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.3.5.3. U.S.: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.3.5.4. U.S.: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.3.6. Rare Disease Genetic Testing Market - Canada
      • 9.3.6.1. Canada: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.3.6.2. Canada: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.3.6.3. Canada: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.3.6.4. Canada: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
  • 9.4. Rare Disease Genetic Testing Market - Europe
    • 9.4.1. Europe: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
    • 9.4.2. Europe: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
    • 9.4.3. Europe: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
    • 9.4.4. Europe: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.4.5. Rare Disease Genetic Testing Market - UK
      • 9.4.5.1. UK: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.4.5.2. UK: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.4.5.3. UK: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.4.5.4. UK: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.4.6. Rare Disease Genetic Testing Market - France
      • 9.4.6.1. France: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.4.6.2. France: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.4.6.3. France: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.4.6.4. France: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.4.7. Rare Disease Genetic Testing Market - Germany
      • 9.4.7.1. Germany: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.4.7.2. Germany: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.4.7.3. Germany: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.4.7.4. Germany: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.4.8. Rare Disease Genetic Testing Market - Italy
      • 9.4.8.1. Italy: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.4.8.2. Italy: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.4.8.3. Italy: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.4.8.4. Italy: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.4.9. Rare Disease Genetic Testing Market - Spain
      • 9.4.9.1. Spain: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.4.9.2. Spain: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.4.9.3. Spain: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.4.9.4. Spain: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.4.10. Rare Disease Genetic Testing Market - Netherlands
      • 9.4.10.1. Netherlands: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.4.10.2. Netherlands: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.4.10.3. Netherlands: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.4.10.4. Netherlands: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.4.11. Rare Disease Genetic Testing Market - Russia
      • 9.4.11.1. Russia: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.4.11.2. Russia.: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.4.11.3. Russia: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.4.11.4. Russia: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
  • 9.5. Rare Disease Genetic Testing Market - Asia Pacific
    • 9.5.1. Asia Pacific: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
    • 9.5.2. Asia Pacific: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
    • 9.5.3. Asia Pacific: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
    • 9.5.4. Asia Pacific: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.5.5. Rare Disease Genetic Testing Market - China
      • 9.5.5.1. China: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.5.5.2. China.: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.5.5.3. China: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.5.5.4. China: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.5.6. Rare Disease Genetic Testing Market - India
      • 9.5.6.1. India: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.5.6.2. India.: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.5.6.3. India: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.5.6.4. India: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.5.7. Rare Disease Genetic Testing Market - Japan
      • 9.5.7.1. Japan: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.5.7.2. Japan.: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.5.7.3. Japan: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.5.7.4. Japan: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.5.8. Rare Disease Genetic Testing Market - Malaysia
      • 9.5.8.1. Malaysia: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.5.8.2. Malaysia.: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.5.8.3. Malaysia: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.5.8.4. Malaysia: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.5.9. Rare Disease Genetic Testing Market - Indonesia
      • 9.5.9.1. Indonesia: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.5.9.2. Indonesia.: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.5.9.3. Indonesia: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.5.9.4. Indonesia: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.5.10. Rare Disease Genetic Testing Market - South Korea
      • 9.5.10.1. South Korea: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.5.10.2. South Korea.: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.5.10.3. South Korea: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.5.10.4. South Korea: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
  • 9.6. Rare Disease Genetic Testing Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
    • 9.6.2. Middle East & Africa: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
    • 9.6.3. Middle East & Africa: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
    • 9.6.4. Middle East & Africa: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.6.5. Rare Disease Genetic Testing Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.6.5.2. Saudi Arabia: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.6.5.3. Saudi Arabia: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.6.5.4. Saudi Arabia: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.6.6. Rare Disease Genetic Testing Market - South Africa
      • 9.6.6.1. South Africa: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.6.6.2. South Africa: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.6.6.3. South Africa: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.6.6.4. South Africa: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.6.7. Rare Disease Genetic Testing Market - Israel
      • 9.6.7.1. Israel: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.6.7.2. Israel: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.6.7.3. Israel: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.6.7.4. Israel: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.6.8. Rare Disease Genetic Testing Market - UAE
      • 9.6.8.1. UAE: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.6.8.2. UAE: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.6.8.3. UAE: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.6.8.4. UAE: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
  • 9.7. Rare Disease Genetic Testing Market - Latin America
    • 9.7.1. Latin America: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
    • 9.7.2. Latin America: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
    • 9.7.3. Latin America: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
    • 9.7.4. Latin America: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.7.5. Rare Disease Genetic Testing Market - Mexico
      • 9.7.5.1. Mexico: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.7.5.2. Mexico: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.7.5.3. Mexico: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.7.5.4. Mexico: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.7.6. Rare Disease Genetic Testing Market - Brazil
      • 9.7.6.1. Brazil: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.7.6.2. Brazil: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.7.6.3. Brazil: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.7.6.4. Brazil: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)
    • 9.7.7. Rare Disease Genetic Testing Market - Argentina
      • 9.7.7.1. Argentina: Rare Disease Genetic Testing Market, by Technology, 2018 - 2030 (USD Million)
      • 9.7.7.2. Argentina: Rare Disease Genetic Testing Market, by End-use, 2018 - 2030 (USD Million)
      • 9.7.7.3. Argentina: Rare Disease Genetic Testing Market, by Specialty, 2018 - 2030 (USD Million)
      • 9.7.7.4. Argentina: Rare Disease Genetic Testing Market, by Disease Type, 2018 - 2030 (USD Million)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. 3billion, Inc
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Ambry Genetics
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Artemis DNA
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Arup Laboratories
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Baylor Genetics
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Centogene N.V
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Color Genomics, Inc
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Coopersurgical, Inc
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Eurofins Scientific
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Fulgent Genetics Inc
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Genomenon
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Health Network Laboratories
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Invitae Corp
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Laboratory Corporation of America Holdings
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Macrogen, Inc
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Myriad Genetics, Inc.
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Opko Health, Inc
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Perkin Elmer, Inc
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development
  • 11.19. PreventionGenetics
    • 11.19.1. Company Overview
    • 11.19.2. Financial Performance
    • 11.19.3. Product Benchmarking
    • 11.19.4. Recent Development
  • 11.20. Progenity, Inc
    • 11.20.1. Company Overview
    • 11.20.2. Financial Performance
    • 11.20.3. Product Benchmarking
    • 11.20.4. Recent Development
  • 11.21. Quest Diagnostics Inc.
    • 11.21.1. Company Overview
    • 11.21.2. Financial Performance
    • 11.21.3. Product Benchmarking
    • 11.21.4. Recent Development
  • 11.22. Realm IDX, Inc
    • 11.22.1. Company Overview
    • 11.22.2. Financial Performance
    • 11.22.3. Product Benchmarking
    • 11.22.4. Recent Development
  • 11.23. Strand Life Sciences.
    • 11.23.1. Company Overview
    • 11.23.2. Financial Performance
    • 11.23.3. Product Benchmarking
    • 11.23.4. Recent Development
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦